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Giant cell tumor of bone (GCTB) is a benign neoplasm but occasionally shows 
local recurrence, and histologically consists of osteoclast-like giant cells (GC) and 
stromal mononuclear cells (SC), which possess the ability of proliferation and 
osteoblastic differentiation. Activation of Wnt signaling can induce osteoblast 
differentiation and osteoclastgenesis during bone resorption process. This study 
analyzed the profiles of β-catenin and cyclin D1 expression in GCTB to elucidate an 
involvement of Wnt pathway in tumorigenesis. We performed immunohistochemistry 
for β-catenin, cyclin D1, and Ki-67 in 16 GCTB tumors, including 5 recurrent cases 
which were surgically resected. All 16 cases of GCTB displayed β-catenin, cyclin D1, 
and Ki-67 expression. Immunoreactivity for β-catenin was observed in nuclei of SC and 
GC. Cyclin D1 immunoreactivity was mainly found in nuclei of GC, while Ki-67 
immunoreactivity was restricted to nuclei of SC. The nuclear β-catenin labeling index 
(LI) in both SC (60.6 vs. 41.8%, p=0.074) and GC (41.7 vs. 20.1%, p=0.095) was 
higher in recurred tumors than in primary tumors in all of 4 cases. However, Ki-67 LI in 
SC (18.8 vs. 19.9%, p=0.851) and cyclin D1 LI in GC (55.4 vs. 70.1%, p=0.225) were 
not higher in recurred tumors than in primary tumors. Our results suggested activation 
of Wnt/ β-catenin pathway in GCTB tumorigenesis. Since cyclin D1 in GC was never 
associated with the expression of the well-known proliferative marker Ki-67, cyclin D1 
expression might exert a role in GC formation instead of promoting cell proliferation 
during GCTB tumorigenesis. Importantly, it was suggested that the level of nuclear 
β-catenin staining might be associated with tumor recurrence in GCTB. 
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Giant cell tumor of bone (GCTB), also known as osteoclastoma, is a benign but 
locally aggressive neoplasm of bone characterized by massive bone destruction at the 
epiphysis of long bone that has a strong tendency for local recurrence. Histologically, 
GCTB consists of numerous scattered multinucleated osteoclast-like giant cells (GC) 
which are the characteristic hallmark of this tumor, and mononuclear stromal cells (SC) 
which represent the true neoplastic (proliferative) component [1]. Although their exact 
origin is as yet undefined, it is likely that SC might originate either from an osteoblastic 
lineage or from bone marrow mesenchymal cells, and regulate the formation of GC in 
the neoplasm. 
Cyclin D1 is a critical cell cycle regulator that drives the cell cycle from the G1 to 
the S phase. Elevated nuclear cyclin D1 expression has been found in human tumors 
including GCTB [2, 3]. We have previously reported that cyclin D1 overexpression is 
significantly correlated with cytoplasmic β-catenin expression in thyroid tumors [4-6]. 
β-catenin has been shown to be a key downstream effector of the Wnt signaling 
pathway to regulate cell growth/survival [7]. This pathway is activated by genetic 
mutations that stabilize the β-catenin protein, which accumulates in the cytoplasm, and 
then translocates to the nucleus. It then binds to the T-cell factor/lymphoid enhancer 
factor (Tcf/Lef) [8-10] to activate genes such as cyclin D1 and contributes to the 
oncogenesis of various human cancers [11-14].  
Recent studies have implicated an important role for Wnt signaling in the 
regulation of skeletal function and have suggested that activation of Wnt signaling can 
induce osteoblast differentiation and osteoclastgenesis during bone resorption process 
Matsubayashi et al. 
[15-17]. This study analyzed the profiles of β-catenin and cyclin D1 expression in 
GCTB to elucidate an involvement of Wnt pathway in its tumorigenesis. In our results, 
we found an increased level of nuclear β-catenin in recurrent GCTB as compared with 
primary tumors. 
 
Subjects and Methods 
 
Materials 
A total of 16 cases of GCTB including 11 primary and 5 recurrent tumors were 
selected from a file of surgically resected specimens performed from 1977 to 2006 in 
our department. These tissues were fixed in 10% buffered formalin and embedded in 
paraffin. Sections 4μm in thickness were routinely stained with hematoxylin and eosin 
and prepared for immunohistochemistry. The clinical profile of each case including 
Campanacci's radiographic grading system [18] and treatment is summarized in Table 1. 
 
Immunohistochemistry 
 After antigen retrieval, sections were immersed in 0.3% H2O2/methanol and, 
subsequently, preincubated with 10% normal goat serum. Then, tissues were incubated 
overnight at 40C with polyclonal anti-β-catenin antibody (GenWay Biotech, San Diego, 
CA) at a 1:50 dilution, monoclonal anti-cyclin D1 antibody (Zymed Labs, South San 
Francisco, CA) at a 1:50 dilution, or monoclonal anti-Ki-67 antibody (DAKO, 
Carpinteria, CA) at a 1:50 dilution. The slides were subsequently incubated with 
biotinylated goat anti-rabbit (for β-catenin) or anti-mouse IgG antibody (for cyclin D1 
and Ki-67) for 1 hr, followed by incubation with avidin-peroxidase for 30 min, and 
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visualized with diaminobenzidine (DAB). A case of callus from a 17 yo-male patient 
was also used as a non-neoplastic tissue control. Control experiments included 
incubation with non-immunized rabbit serum (for β-catenin) or mouse serum (for cyclin 
D1 and Ki-67) instead of the primary antibodies. They did not show any staining.  
 
Evaluation of immunohistochemical results 
Tumor cells with nuclear and/or cytoplasmic staining were considered as positive 
in immunohistochemistry for β-catenin, while only tumor cells with nuclear staining 
were considered as positive in immunohistochemistry for cyclin D1 and Ki-67. The 
number of β-catenin, cyclin D1, and Ki-67 positive cells was counted in five different 
tumor areas at 200-fold magnification, and the percentage of immunoreactive cells from 
the total number of SC or GC was calculated as the labeling index (LI) in each case. For 
statistical analysis, the paired Student’s t-test was used to assess differences in the 
β-catenin, cyclin D1, and Ki-67 LI between primary and recurrent tumors. Associations 
between the β-catenin, cyclin D1, and Ki-67 LI and Campanacci’s radiographic grading 
were assessed by using the Jonckheere-Terpstra test. A p-value of less than 0.05 was 




 All 16 cases of GCTB displayed β-catenin, cyclin D1, and Ki-67 expression. 
Immunoreactivity for β-catenin was observed in nuclei of SC and in nuclei and/or 
cytoplasms of GC (Fig. 1A and D). Cyclin D1 immunoreactivity was mainly found in 
nuclei of GC and, occasionally, in a much small number of SC (Fig. 1B and E), while 
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Ki-67 immunoreactivity was restricted to nuclei of SC (Fig. 1C and F). Nuclear 
immunoreactivities of both β-catenin and cyclin D1 were observed throughout almost 
all nuclei in a GC showing staining. The co-localization of β-catenin and cyclin D1 
immunoreactivity were shown in nuclei of GC by using serial sections (Fig. 2).  
 In comparison of immunohistochemical results between GC in which the number 
of nuclei was less than 15 (GC<15) and GC in which the number of nuclei was 15 or 
more (GC≥15), statistical analyses revealed that both β-catenin and cyclin D1 LI were 
significantly higher in GC<15 than GC≥15 (p<0.001, respectively). Furthermore, 
although there was no significant difference, nuclear β-catenin LI in both SC (60.6 vs. 
41.8%, p=0.074) and GC<15 (41.7 vs. 20.1%, p=0.095) were higher in recurred tumors 
than in primary tumors in all of 5 cases. However, Ki-67 LI in SC (18.8 vs. 19.9%, 
p=0.851) and cyclin D1 LI in GC<15 (55.4 vs. 70.1%, p=0.225) was not higher in 
recurred tumors than in primary tumors. On the basis of Campanacci’s radiographic 
grading, although there was no significant difference between the mean value of 
β-catenin/cyclin D1 LI in tumor and grading of case, Ki-67 LI in SC was significantly 
increased with a higher level of grade (14.5, 23.1, and 24.0% in grade I, II, and III, 
respectively, p=0.033). Immunohistochemical results for each case are presented in 
Table 2, and these results are summarized in Tables 3 and 4. 
 In a case of callus, immunoreactivity for β-catenin was observed only in nuclei and 
cytoplasms of osteoblasts lining the surface of bone trabecule but not in osteoclasts (Fig. 
3A and B). However, cyclin D1 immunoreactivity was found in neither osteoblasts nor 
osteoclasts (Fig. 3C and D). 
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Discussion 
 
GCTB histologically consists of osteoclast-like GC and SC, which possess the 
ability of proliferation and osteoblastic differentiation. Wnt signaling has been shown to 
play a substantial role in the control of bone formation. This study analyzed the 
immunohistochemical profile of β-catenin and cyclin D1 expression in GCTB to 
elucidate an involvement of Wnt pathway in tumorigenesis. It is well established that 
the cytoplasmic stabilization of β-catenin via Wnt signaling leads to translocation of 
β-catenin into the nucleus and subsequent activation of cyclin D1 transcription [19]. 
Our results demonstrated both β-catenin and cyclin D1 expressions in all cases of 
GCTB. Furthermore, immunostainings with serial sections revealed the co-localization 
of β-catenin and cyclin D1expression in nuclei of GC, suggesting a role of activated 
Wnt/β-catenin pathway during GCTB tumorigenesis. However, activation of Wnt 
signaling can induce osteoblast differentiation and negatively regulate osteoclastgenesis 
through osteoblast during a physiological bone resorption process [20, 21]. Actually, 
nuclear β-catenin expression was revealed only in osteoblatsts but not in osteoclasts 
which appeared in callus tissue as an activated state of bone remodeling. These 
observations suggest Wnt/β-catenin might be abnormally activated in GC during GCTB 
tumorigenesis. Thus, molecular analyses regarding its activation machinery remain to 
be elucidated. 
Similarly to a previous report [3], cyclin D1 staining in GC was never associated 
with the expression of Ki-67. Due to the fact that Ki-67 is a well characterized 
proliferation marker which is expressed by all cells undergoing cell cycle, we 
hypothesized that nuclear cyclin D1 protein might function mainly in a role instead of 
8 
Matsubayashi et al. 
promoting cell proliferation. However, the functional role of cyclin D1 expression in 
GC of GCTB tumorigenesis is not fully understood. Interestingly, the level of cyclin D1 
immunoreactivity was significantly higher in GC<15 than GC≥15. Thus, cyclin D1 
expression may play a role on the maturation and multinucleation of GC in GCTB. 
Indeed, cyclin D1 protein overexpression has been shown to be associated with giant 
cell formation, multinucleation, and increased ploidy in different cell models [22-25]. 
Further studies are required to elucidate the functional role of cyclin D1 overexpression 
on GC formation during GCTB tumorigenesis. 
GCTB can be locally aggressive with a tendency for recurrence whose clinical 
behavior is difficult to predict based on its microscopic appearance alone [26]. 
Campanacci's radiographic grading system has been considered as a reliable predictive 
factor of local recurrence in GCTB [18]. Our statistical analysis revealed that a case of 
higher Campanacci's radiographic grade seems to exhibit a high proliferative activity of 
SC component. In our subjects, 5 of 16 cases were with recurrence. It is worthy to note 
that the level of nuclear β-catenin expression in both SC and GC was higher in recurred 
tumors than in primary tumors in all cases, although there was no significant difference. 
Similarly, although there was no significant difference, the level of nuclear β-catenin 
immunoreactivity in SC was going up with higher Campanacci's grading. Thus, the 
level of nuclear β-catenin immunoreactivity might be related with tumor recurrence in 
GCTB. However, because the level of Ki-67 staining in SC was not higher in recurred 
tumor than in primary, the level of nuclear β-catenin expression was not directly 
associated with the proliferative activity of SC, which is considered as the true 
neoplastic component, in tumor recurrence [1, 26-28]. Biological activity other than 
proliferative capability of tumor cells, which was regulated by Wnt/β-catenin pathway, 
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might be important in recurrence of GCTB. 
In summary, the present study demonstrated a frequent expression of both 
β-catenin and cyclin D1 proteins in GCTB. Furthermore, immunoreactivity for 
β-catenin localized to nuclei of both SC and GC, suggesting an activation of Wnt/ 
β-catenin pathway in GCTB tumorigenesis. Cyclin D1 staining in GC was never 
associated with the expression of the well-known proliferative marker, Ki-67, and the 
level of cyclin D1 immunoreactivity was mainly expressed in GC possessing fewer 
nuclei. Thus, cyclin D1 expression might exert a role in GC formation instead of 
promoting cell proliferation during GCTB tumorigenesis. Importantly, it is suggested 
that the level of nuclear β-catenin staining might be associated with tumor recurrence in 
GCTB. Thus, additional studies are needed to further clarify the functional role of 
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Figure 1. Immunohistochemical analysis for β-catenin, cyclin D1, and Ki-67 expression 
in primary (A-C) and recurrent cases (D-F) of giant cell tumor of bone (GCTB). A 
primary case of GCTB showed cytoplasmic β-catenin expression in osteoclast-like giant 
cells (GC) (A), while recurrent GCTB widely showed nuclear β-catenin expression in 
both GC and stromal mononuclear cells (SC) (D). Insets in both A and D display 
representative cytoplasmic and nuclear β-catenin immunoreactivity in tumor cells, 
respectively. Cyclin D1 immunoreactivity was found in nuclei of GC in primary case 
(B) and in nuclei of both GC and SC in recurrent case (E). Arrows indicate cyclin 
D1-positive GC in which the number of nuclei was less than 15, while asterisks indicate 
cyclin D1-negative GC in which the number of nuclei was 15 or more. Ki-67 
immunoreactivity was restricted to nuclei of SC but not in GC (C and F). No apparent 
difference is evident in the level of cyclin D1 expression between primary (C) and 
recurrent (F) cases[u1][u2]. 
 
Figure 2. Co-localization of β-catenin (A) and cyclin D1 (D) immunoreactivity in 
nuclei of osteoclast-like giant cells (GC) by using serial sections. Arrows indicate 
double-positive GC, while asterisks indicate double-negative GC. 
 
Figure 3. Immunohistochemical analysis for β-catenin (A, B) and cyclin D1 (C, D) 
expression in a case of callus as a non-neoplastic tissue control. Nuclear staining for 
β-catenin was observed in osteoblasts but not in osteoclasts, while no cyclin D1 
























Recurrent Age Size [mm] Site 
Campanacci’s 
grading Curettage Burning Spacer 
1 M Primary 33 53x35x30 tibia I + ethanol artificial bone 
  Recurrent 34 30x30x25 tibia II + airtome, ethanol polymethylmetacrylate 
2 F Primary 17 30x30x25 tibia I + airtome artificial bone 
  Recurrent 17 35x30x30 tibia I + airtome, ethanol polymethylmetacrylate 
3 F Primary 62 60x60x35 femur I + airtome polymethylmetacrylate 
4 F Primary 28 60x55x35 sacrum I -, radiation - - 
5 M Primary 59 60x50x40 tibia I + - - 
6 M Primary 55 100x45x40 humerus III + - artificial bone 
  Recurrent 57 100x48x44 humerus III + ethanol polymethylmetarylate 
7 M Primary 23 40x20x20 radius II + ethanol artificial bone 
  Recurrent 23 40x20x20 radius II + ethanol artificial bone 
8 M Primary 22 70x60x43 humerus III +, radiation ethanol artificial and autobone 
9 F Primary 58 43x40x25 fibula III wide resection - - 
10 F Primary 17 78x45x38 femur II + - polymethylmetacrylate 
  Recurrent 35 60x50x40 femur III + - polymethylmetacrylate 
11 M Primary 44 33x23x22 radius III wide resection - - 











β-catenin [%] Ki-67 [%] β-catenin [%] Cyclin D1 [%] β-catenin [%] Cyclin D1 [%] 
1 M Primary I 21.9 11.6 31.3 84.6 3.1 7.3 
  Recurrent II 68.1 28.1 42.9 86.6 15.9 7.2 
2 F Primary I 56.6 17.0 20.8 53.3 25.0 36.7 
  Recurrent I 61.6 7.0 26.1 33.3 8.7 6.7 
3 F Primary I 52.0 13.3 65.0 80.2 13.3 17.6 
4 F Primary I 63.2 10.2 50.0 72.5 6.0 8.2 
5 M Primary I 17.9 28.1 8.3 78.9 0 6.1 
6 M Primary III 44.5 22.9 0 67.1 0 26.8 
  Recurrent III 67.2 25.3 2.4 74.4 4.8 23.9 
7 M Primary II 26.5 14.5 0 70.5 0 9.0 
  Recurrent II 44.3 16.4 54.2 58.5 0 0 
8 M Primary III 58.7 35.1 49.1 69.4 3.9 4.2 
9 F Primary III 48.3 18.4 51.4 69.2 16.8 5.3 
10 F Primary II 59.6 33.5 48.4 75.2 22.6 1.2 
  Recurrent III 62.0 17.0 82.8 24.2 3.5 0 
11 M Primary III 69.3 25.4 80.9 71.9 4.8 1.1 
 





Nuclear <15 Nuclear ≥15 Primary or 
















6 45.5 54.4x48.0x32.8 51.6 21.8 50.8 73.7 7.5 7.1 
Primary with 
recurrence 
5 29.0 60.2x35.0x30.6 41.8 19.9 20.1 70.1 10.1 16.2 
Recurrent 5 33.2 53.0x35.6x32.2 60.6 18.8 41.7 55.4 6.6 7.6 
P-value*    0.074 0.851 0.095 0.225 0.593 0.195 
 
*Primary with recurrence vs. Recurrent 
 





Nuclear <15 Nuclear ≥15 Campanacci’s 










Cyclin D1  
[%] 
I 6 36.0 5/1 45.5 14.5 33.6 67.1 9.4 13.8 
II 4 24.3 2/2 49.6 23.1 36.4 72.7 9.6 4.4 
III 6 45.2 4/2 58.3 24.0 44.4 62.7 5.6 10.2 
P-value*    0.209 0.033 0.468 0.288 0.592 0.227 
 
*Jonckheere-Terpstra test among Campanacci’s radiographic grading 
